Dr. Andrew Hislop is currently the acting head of the Cell and Tissue Therapies Unit at the Therapeutic Goods Administration (TGA). Andrew has worked at the TGA as a senior evaluator for the last four years predominantly in the Biological Medicines Unit. Prior to this Andrew spent over 25 years studying cellular immunity to oncogenic viruses in various international research institutes.